« Back
Association of Nonalcoholic Fatty Liver Disease with Insulin Resistance in Type 2 Diabetes Mellitus – A prospective study
Association of Nonalcoholic Fatty Liver Disease with Insulin Resistance in Type 2 Diabetes Mellitus – A prospective study
Submitted on 12 Nov 2017

Jasim Jalal; Shobha P; Nisha N; Shani Basheer; Nelson Joseph
Department of Family Medicine, VPS Lakeshore Hospital, Kochi, Kerala, India
This poster was presented at MUZIRISCON 2017
Poster Views: 617
View poster »
Poster Abstract
Background: Association of Nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM) is common.
Materials and Methods: Our study population included 100 patients of T2DM. Presence of fatty liver in these patients was determined by abdominal sonography. Insulin Resistance was assessed by Homeostasis Model Assistant - Insulin Resistance (HOMA-IR).
Results: The study group (n = 100) was divided into a NAFLD group (n = 55) and a non-NAFLD group (n = 45). The prevalence of NAFLD in our study was 55%. The prevalence of obesity, central obesity was higher in NAFLD group with increased values of HbA1c and triglyceride levels. Insulin Resistance was significantly higher in NAFLD group.

Conclusion: Presence of NAFLD among T2DM patients is significantly associated with Insulin resistance.

1. Kral JG, Schaffner F, Pierson RN Jr, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism 1993; 42:548‑51.

2. Gastaldelli A, Miyazaki Y, Pettiti M, Matsuda M, Mahankali S, Santini E, et al. Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab 2002; 87:5098‑103.

3. Adams LA, Angulo P. Recent concepts in non‑alcoholic fatty liver disease. Diabet Med 2005; 22:1129‑33.

4. Bayard M, Holt J, Boroughs E. Nonalcoholic fatty liver disease. Am Fam Physician 2006; 73:1961‑8.

5. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8:521‑33.
Report abuse »
Creative Commons

Related Posters

Referral Lab
Viajy Kumar Ranka

Оценка противоболевой и противовоспалительной активности гимантана в наружной гелевой лекарственной форме
Matyushkin Alexander, Ivanova Elena

High-throughput Carbonic Anhydrase Activity and Inhibitor Screening Assays
Suratna Hazra, Ph.D., Grigoriy Tchaga, Ph.D., and Gordon Yan, Ph.D.

A High-Throughput Assay to Measure Phosphoenolpyruvate Carboxykinase (PEPCK) Activity in Biological Samples
Shunan Li, Ph.D., Keith Cheung, Ph.D. Grigoriy Tchaga, Ph.D. Jianping Xu, Ph.D. and Gordon Yan, Ph.D. Acknowledments: Kyle Schmitt, Ph.D • Tanvi Gangakhedkar • Gustavo Chavarria, Ph.D. • Kwang Kim, Ph.D. • Robert Stephenson, Ph.D. • Hong Qu, Ph.D.

Estratificación de fragilidad y su relación con las comorbilidades más frecuentes en la residencia Ballesol
Rico Gallegos Carina Guadalupe, Vargas Esparza Maria Goretti